Tarsus Free Cash Flow vs Capital Expenditures Analysis

TARS Stock  USD 52.50  1.42  2.78%   
Tarsus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Tarsus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tarsus Pharmaceuticals is a good investment. Please check the relationship between Tarsus Pharmaceuticals Free Cash Flow and its Capital Expenditures accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

Free Cash Flow vs Capital Expenditures

Free Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tarsus Pharmaceuticals Free Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have pay attention.
The correlation between Tarsus Pharmaceuticals' Free Cash Flow and Capital Expenditures is -0.95. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Tarsus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Tarsus Pharmaceuticals' Free Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Tarsus Pharmaceuticals are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Free Cash Flow i.e., Tarsus Pharmaceuticals' Free Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

-0.95
Relationship DirectionNegative 
Relationship StrengthSignificant

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Capital Expenditures

Capital Expenditures are funds used by Tarsus Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Tarsus Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most indicators from Tarsus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tarsus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.At this time, Tarsus Pharmaceuticals' Tax Provision is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 84.3 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.87 in 2024.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation312K325K628K659.4K
Total Operating Expenses67.1M87.6M159.0M167.0M

Tarsus Pharmaceuticals fundamental ratios Correlations

0.840.810.980.980.89-0.87-0.810.740.920.771.00.651.00.960.350.920.920.650.990.761.01.01.01.00.96
0.841.00.80.790.98-0.82-0.990.980.780.990.820.940.820.810.350.820.970.650.820.980.840.840.820.840.73
0.811.00.760.750.98-0.81-0.990.990.760.990.790.960.790.780.360.780.960.660.780.990.80.810.780.810.7
0.980.80.761.00.85-0.86-0.750.680.90.720.980.580.980.90.160.920.90.491.00.710.980.980.980.980.96
0.980.790.751.00.84-0.85-0.750.680.910.710.980.580.980.90.170.920.890.511.00.70.980.980.980.980.96
0.890.980.980.850.84-0.91-0.960.950.870.970.870.890.870.860.330.870.980.640.870.970.880.890.870.890.81
-0.87-0.82-0.81-0.86-0.85-0.910.77-0.77-0.97-0.82-0.87-0.69-0.86-0.87-0.29-0.85-0.87-0.56-0.85-0.83-0.87-0.87-0.87-0.87-0.89
-0.81-0.99-0.99-0.75-0.75-0.960.77-0.99-0.74-0.98-0.78-0.97-0.79-0.78-0.38-0.76-0.95-0.68-0.78-0.97-0.8-0.81-0.78-0.81-0.7
0.740.980.990.680.680.95-0.77-0.990.720.990.710.990.720.730.370.70.930.660.710.980.740.750.710.750.64
0.920.780.760.90.910.87-0.97-0.740.720.770.910.630.910.90.310.890.850.60.890.780.920.920.910.920.92
0.770.990.990.720.710.97-0.82-0.980.990.770.750.970.750.750.360.770.940.650.741.00.770.770.750.770.67
1.00.820.790.980.980.87-0.87-0.780.710.910.750.620.990.960.340.910.910.630.990.741.01.01.01.00.97
0.650.940.960.580.580.89-0.69-0.970.990.630.970.620.630.640.390.620.870.650.610.960.650.660.620.660.54
1.00.820.790.980.980.87-0.86-0.790.720.910.750.990.630.960.350.910.90.660.980.741.01.00.991.00.96
0.960.810.780.90.90.86-0.87-0.780.730.90.750.960.640.960.570.850.870.80.90.750.960.960.960.960.93
0.350.350.360.160.170.33-0.29-0.380.370.310.360.340.390.350.570.180.290.910.180.360.340.350.340.350.27
0.920.820.780.920.920.87-0.85-0.760.70.890.770.910.620.910.850.180.860.530.920.780.910.910.90.910.82
0.920.970.960.90.890.98-0.87-0.950.930.850.940.910.870.90.870.290.860.610.910.930.920.920.910.920.85
0.650.650.660.490.510.64-0.56-0.680.660.60.650.630.650.660.80.910.530.610.520.650.650.660.630.660.55
0.990.820.781.01.00.87-0.85-0.780.710.890.740.990.610.980.90.180.920.910.520.730.990.980.980.980.96
0.760.980.990.710.70.97-0.83-0.970.980.781.00.740.960.740.750.360.780.930.650.730.760.760.730.760.66
1.00.840.80.980.980.88-0.87-0.80.740.920.771.00.651.00.960.340.910.920.650.990.761.01.01.00.96
1.00.840.810.980.980.89-0.87-0.810.750.920.771.00.661.00.960.350.910.920.660.980.761.01.01.00.96
1.00.820.780.980.980.87-0.87-0.780.710.910.751.00.620.990.960.340.90.910.630.980.731.01.01.00.97
1.00.840.810.980.980.89-0.87-0.810.750.920.771.00.661.00.960.350.910.920.660.980.761.01.01.00.96
0.960.730.70.960.960.81-0.89-0.70.640.920.670.970.540.960.930.270.820.850.550.960.660.960.960.970.96
Click cells to compare fundamentals

Tarsus Pharmaceuticals Account Relationship Matchups

Tarsus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets58.3M172.0M178.9M227.9M265.5M165.9M
Other Current Liab299K2.9M7.3M9.2M18.4M19.3M
Total Current Liabilities819K5.4M11.5M15.4M36.9M38.8M
Total Stockholder Equity(6.0M)166.0M166.7M192.9M197.0M131.1M
Net Tangible Assets(6.0M)166.0M166.7M192.9M221.8M114.0M
Property Plant And Equipment Net280K1.2M1.8M1.5M3.3M3.5M
Net Debt(57.8M)(167.3M)(169.4M)(51.5M)(193.2M)(183.6M)
Retained Earnings(6.0M)(32.8M)(46.7M)(108.8M)(244.7M)(232.4M)
Accounts Payable456K2.2M2.9M5.5M18.1M19.1M
Cash58.0M168.1M171.3M71.7M224.9M127.7M
Non Current Assets Total286K1.3M3.0M2.5M9.4M9.8M
Cash And Short Term Investments58.0M168.1M171.8M217.0M227.4M154.9M
Net Receivables36K20K92K3.6M17.7M18.6M
Common Stock Shares Outstanding19.5M20.3M20.6M24.6M29.4M21.8M
Liabilities And Stockholders Equity58.3M172.0M178.9M227.9M265.5M165.9M
Non Current Liabilities Total63.5M605K699K19.5M31.6M21.9M
Capital Lease Obligations164K831K1.9M773K398K743.8K
Other Current Assets22K2.5M8.1M4.8M7.9M4.3M
Other Stockholder Equity27K198.8M213.4M301.7M441.6M463.7M
Total Liab64.3M6.0M12.2M35.0M68.5M34.8M
Net Invested Capital(6.0M)166.0M166.7M212.3M226.8M140.2M
Property Plant And Equipment Gross280K548K1.8M957K4.6M4.9M
Total Current Assets58.0M170.7M176.0M225.4M256.1M162.9M
Net Working Capital57.2M165.3M164.5M209.9M219.2M150.0M
Property Plant Equipment280K1.2M755K957K1.1M711.5K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.